As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...
Clinical Trials Arena on MSN2d
Duchenne muscular dystrophy: Five trials to watchAmid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.
The exon-skipping drug was approved by the FDA for DMD patients with mutations in the dystrophin gene amenable to exon 53 skipping, a group that accounts for around 8% of the total DMD population.
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...
PepGen is pausing the initiation of a new Phase II Duchenne muscular dystrophy (DMD ... including a mean exon skipping level of 2.15% and a 0.26% increase from baseline of absolute dystrophin ...
Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback